Clinical Benefit of Bempedoic Acid in Randomized Clinical Trials.

[1]  P. Libby,et al.  Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients. , 2023, JAMA.

[2]  D. Grobbee,et al.  Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. , 2023, The New England journal of medicine.

[3]  M. Banach,et al.  Long-Term Safety and Efficacy of Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from the CLEAR Harmony Open-Label Extension Study). , 2022, The American journal of cardiology.

[4]  M. Mazidi,et al.  Prevalence of statin intolerance: a meta-analysis , 2022, European heart journal.

[5]  A. A. Asbeutah,et al.  A Meta-Analysis of Cardiovascular Outcomes in Patients With Hypercholesterolemia Treated With Bempedoic Acid. , 2020, The American journal of cardiology.

[6]  Lawrence A Leiter,et al.  Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial. , 2019, JAMA.

[7]  G. Hindricks,et al.  2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. , 2019, Atherosclerosis.

[8]  D. Gaudet,et al.  Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance , 2019, Journal of the American Heart Association.

[9]  C. Ballantyne,et al.  Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol , 2019, The New England journal of medicine.

[10]  I. Olkin,et al.  Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement , 1999, The Lancet.